AVEN

Across TCGA pan-cancer cohorts, AVEN Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AVEN data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AVEN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AVEN expression acts as an unfavorable survival marker.

HNSC, LUAD, and ESCA are the cancer types where AVEN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.057	0.757	<.001	36	view →
LUAD	OS	Median	III,IV	0.068	0.680	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AVEN–HNSC (OS)

Open the HNSC breakdown →